The DOI matches its Crossref record.
The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers
Abstract
The use of agonistic analogues of luteinizing hormone releasing hormone (LHRH) is an established therapy for hormone-dependent metastatic pre-menopausal breast cancer. Their mechanism of action in this disease is the suppression of ovarian oestrogen production (medical castration). In the treatment of post-menopausal metastatic breast cancer, LHRH agonists also have some effect, although minor, probably through a suppression of ovarian androgen production. Convincing evidence has been accumulated that LHRH analogues can directly inhibit the proliferation of breast cancer cells in vitro. The clinical impact of these findings, however, is still controversial. Experimental data and several pilot clinical trials suggest that in epithelial ovarian cancer and sex-cord-stromal tumours of the ovary, LHRH agonists might have antitumour activity through the suppression of gonadotrophin secretion (selective medical hypophysectomy). Phase III clinical trials, evaluating this hypothesis, are in progress. Direct antiproliferative effects of LHRH analogues on epithelial ovarian cancer cells have been demonstrated in vitro. In endometrial cancer, experimental and early clinical results support the concept of a direct antiproliferative activity of LHRH analogues. Recently, potent antagonistic analogues of LHRH, devoid of relevant side-effects have become available for clinical testing. These new antagonists might be superior to agonistic LHRH analogues with respect to the rapidity and efficacy of selective medical hypophysectomy and medical castration. Modern LHRH antagonists might also permit a better exploitation of direct antitumour effects. A further therapeutic improvement in gynaecological oncology might result from a combination of LHRH agonists or antagonists with other peptide hormone analogues such as agonists of somatostatin or antagonists of bombesin/gastrin releasing peptide which have antitumour activity. Since 50% of breast cancers and 80% of epithelial ovarian cancers and endometrial cancers have high affinity binding sites for LHRH, cytotoxic LHRH analogues might provide a targeted chemotherapy, which would be more efficacious and less toxic than conventional regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Reubi, J. C. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0007 · Cited by 1,131
Gonadotropin-Releasing Hormone Receptors
Millar, R. P., Lu, Z.-L., Pawson, A. J., Flanagan, C. A., Morgan, K., & Maudsley, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0002 · Cited by 794
Molecular Mechanisms of Ligand Interaction with the Gonadotropin-Releasing Hormone Receptor
Sealfon, S. C., Weinstein, H., & Millar, R. P. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.2.0295 · Cited by 515
Millar, R. P. (2005) · Animal Reproduction Science · doi:10.1016/j.anireprosci.2005.05.032 · Cited by 423
GnRH II and type II GnRH receptors
Millar, R. P. (2003) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(02)00016-4 · Cited by 280
Metadata
- Authors
- Emons, G., & Schally, A. V.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 1994-07
- Volume
- 9
- Issue
- 7
- Pages
- 1364-1379
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2292879214
- Cited by
- 244
- References
- 0
- FWCI
- 13.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. https://app.cochat.ai/papers/10.1093/oxfordjournals.humrep.a138714
- The paper
- Emons, G., & Schally, A. V. (1994). The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Human Reproduction. https://doi.org/10.1093/oxfordjournals.humrep.a138714
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.